- Raised $7M funding round, Jul 2016
- Raised $3M funding round, Jan 2015
About
PamBio is a biotechnology company developing drug therapy for hemorrhagic stroke (e.g. intracranial bleeding and ICH) and other acute bleeding conditions. PamBio's solution for ICH drug treatment is an inactive recombinant mutant-tPA protein. Its S481A amino-acid substitution renders the protein catalytically inactive but maintains its structure and ability to interact with major components of the fibrinolytic pathway. In essence, the mutant-tPA drug molecule is a competitive inhibitor to the native-tPA. This therapeutic biomolecule has a dual antifibrinolytic and neuroprotective effect. It blocks both tPA and uPA fibrinolysis enzyme activity, enabling treatment beyond three hours, and it limits tPA and glutamate-mediated neurotoxicity by blocking the binding of the neurotoxic tPA to NMDA receptors, thus providing neuroprotection. PamBio is an NGT3 VC portfolio company.
Funding history · 2 rounds · $10.0M total
Q&A
- What is PamBio's primary focus?
- PamBio is a biotechnology company developing drug therapy for hemorrhagic stroke and other acute bleeding conditions.
- What is PamBio's solution for intracranial hemorrhage (ICH) drug treatment?
- PamBio's solution for ICH drug treatment is an inactive recombinant mutant-tPA protein. This therapeutic biomolecule has a dual antifibrinolytic and neuroprotective effect, blocking tPA and uPA fibrinolysis enzyme activity and limiting tPA and glutamate-mediated neurotoxicity.
- When was PamBio founded?
- PamBio was founded in April 2014.
- What is PamBio's current operational status?
- PamBio is currently inactive and ceased to operate in January 2019.
- How much funding has PamBio raised in total?
- PamBio has raised a total of $10,000,000 USD.
- When was PamBio's last funding round and how much was raised?
- PamBio's last funding round was in July 2016, raising $7,000,000 USD.
- Which investors participated in PamBio's January 2015 funding round?
- In January 2015, PamBio received funding from NGT3 and the Office of the Chief Scientist.
- Who are the founders of PamBio?
- The founders of PamBio are Abd Al-Roof Higazi, Prof., MD, and Dr. Nuha Higazi.
Team · 2
Sectors & technology
Tags
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
Identifiers & details
| Founded | 2014-4 |
|---|---|
| Employees (exact) | 6 |
| Status reason | Non Active, Jan 2019 ceased to operate |